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Cardiomyocyte function depends on coordinated movements of calcium into and out of the cell and the
proper delivery of ATP to energy-utilizing enzymes. Defects in calcium-handling proteins and abnormal en-
ergy metabolism are features of heart failure. Recent discoveries have led to gene-based therapies targeting
calcium-transporting or -binding proteins, such as the cardiac sarco(endo)plasmic reticulum calciumATPase
(SERCA2a), leading to improvements in calcium homeostasis and excitation-contraction coupling. Here we
review impaired calcium cycling and energetics in heart failure, assessing their roles from both a mutually
exclusive and interdependent viewpoint, and discuss therapies that may improve the failing myocardium.Introduction
Congestive heart failure is the leading cause of morbidity and
mortality worldwide, resulting in an extensive economic burden
to healthcare systems. Despite recent advances in pharmaco-
logical and device therapies, rates of heart disease continue to
rise due to an aging population; therefore, new treatment options
are urgently needed. An understanding of heart disease at a mo-
lecular level and the identification of key transporters and pro-
teins affected during pathogenesis has paved the way for new
strategies to treat heart disease, namely the calcium-handling
proteins in the sarcoplasmic reticulum (SR).
As a secondmessenger, calcium hasmany signaling roles and
is involved in processes ranging from cell death to muscle
contraction (Berridge et al., 2000). It is the maintenance of a cal-
cium gradient across endoplasmic or SR membranes generated
by calcium channels, ATPase pumps, transporters, and ex-
changers working in synergy with calcium-binding proteins
that allows these processes to occur. The contractile function
of cardiomyocytes is controlled by excitation-contraction (EC)
coupling, which results in rapid changes in intracellular calcium
concentration leading to contraction (systole) and relaxation
(diastole) (Figure 1). During systole, an action potential causes
the depolarization of the plasmamembrane (sarcolemma), which
results in the entry of a small amount of extracellular calcium into
the cytosol through the voltage-gated L-type calcium channel
(LTCC). This calcium binds to the ryanodine receptor (RyR2),
triggering a massive efflux of calcium from the SR into the
cytosol; this process is termed calcium-induced calcium
release. This approximately 10-fold increase in cytosolic calcium
concentration activates calcium-sensitive contractile proteins
(troponin C; TN-C), which then use ATP to produce tension
and muscle contraction. For muscle relaxation to occur, calcium
is removed from the cytosol—approximately 30% is transported
out of the cell (primarily by the sodium-calcium exchanger [NCX]
and plasma membrane calcium ATPase [PMCA]) while 70% is
pumped back into the SR via the cardiac SR calcium ATPase
(SERCA2a) (Bers, 2008).EC coupling is modulated by many signaling pathways,
including the b-adrenergic pathway. Activation of the b-adren-
ergic pathway by b-agonists, such as adrenaline, initiates the
production of cyclic AMP (cAMP) by adenylate cyclase, which
activates protein kinase A (PKA) (Antos et al., 2001). This results
in the downstream phosphorylation of multiple targets in the car-
diomyocyte that collectively produce an increase in the fre-
quency and strength of contraction (Feldman and Gros, 2007).
For example, PKA phosphorylates the SERCA2a modulator,
phospholamban (PLN), resulting in relief of inhibition and an in-
crease in the quantity and rate of cytosolic calcium removal
back into the SR (Haghighi et al., 2004); phosphorylation of the
LTCC increases calcium current and force of contraction
(Kamp and Hell, 2000); and troponin I has reduced sensitivity
to calcium when phosphorylated, leading to increased calcium
removal from the cytosol (Li et al., 2000). Therefore, activation
of the b-adrenergic pathway results in both an increase in rate
of contraction (positive inotropy) and relaxation (positive lusi-
tropy) (Lohse et al., 2003).
Balanced cardiac energetics are crucial to proper contractile
function, as energy-producing and -utilizing pathways are tightly
regulated in the heart. ATP is primarily produced by oxidative
phosphorylation in the mitochondria (>95%), with small contri-
butions made by substrate-level phosphorylation and the tricar-
boxylic acid (TCA) cycle (<5%) (Ingwall, 2009). The major ATP
users in the heart are the actomyosin ATPase in the myofibril,
SERCA2a in the SR, and PMCA and Na,K-ATPase in the sarco-
lemma (Figure 2). The concentration of ATP in the heart is kept
relatively constant (10 mM) despite the relatively high energy de-
mand necessary for cardiac performance (Ingwall, 2009). The
energetic state of the heart is also dependent on levels of phos-
phocreatine (PCr), which is the primary energy reserve source in
the heart and is present at levels twice that of ATP (Bittl and Ing-
wall, 1985).
In patients with cardiac disease, defects in both systolic and
diastolic function have been reported. During heart disease,
gross physiological changes in the heart, such as increasedCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 183
Figure 1. Excitation-Contraction Coupling
in Cardiac Myocytes
During systole, an action potential depolarizes the
sarcolemma and induces opening of the LTCC,
allowing aminor amount of extracellular calcium to
enter the cytosol (step 1). In turn, this initiates
massive calcium release from the SR through the
RyR2 channels (step 2). This sudden increase in
cytosolic calcium concentration results in binding
of calcium to TN-C and initiation of muscle
contraction (step 3). The rapid removal of cytosolic
calcium during diastole is primarily facilitated by
SERCA2a, which returns calcium to the SR
(step 4). Some calcium also exits the cell through
NCX and PMCA (step 5). This decrease in intra-
cellular calcium leads to dissociation of calcium
from TN-C and muscle relaxation. Na,K-ATPase,
sodium-potassium ATPase; PMCA, plasma
membrane calcium ATPase; NCX, sodium calcium
exchanger; LTCC, voltage-dependent L-type
calcium channel; RyR2, ryanodine receptor iso-
form 2; CASQ2, calsequestrin isoform 2; HRC,
histidine-rich calcium-binding protein; SERCA2a,
sarco(endo)plasmic reticulum calcium ATPase;
PLN, phospholamban; TN-C, troponin-C.
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panied by myocyte morphological changes, including an
increase in length/size, sarcomeric disorganization, and myofi-
brillar disarray (Harvey and Leinwand, 2011; Kehat and
Molkentin, 2010). These abnormalities often stem from changes
in calcium homeostasis caused by altered expression or function
of calcium transporting or binding proteins.Whether the cause or
result of this, the failing heart also hasmultiple defects in both en-
ergy supply and demand, which altogether result in an organ that
is both energy starved and ill functioning. In this Review, we will
discuss the role of calcium homeostasis, particularly in terms of
SR calcium handling, and how it relates to energy metabolism in
heart failure. Wewill also overview the therapeutic advantages of
targeting calcium-handling proteins in terms of benefits for both
EC coupling and cardiac energetics when pertinent.
Impaired Calcium Cycling in Heart Failure
Defects in EC coupling, due to abnormal expression and/or func-
tion of calcium-handling and -transport proteins, are a hallmark
of cardiac dysfunction. These defects manifest in changes in
the calcium transient: reduced amplitude, increased duration,
and prolonged decay—the consequence of which is decreased
contractility and reduced cardiac output. In the next subsec-
tions, the role of reduced SR calcium load during heart failure
will be discussed in terms of excessive calcium entry into the
cytosol, decreased SR calcium uptake, decreased SR calcium
content, and calcium leak from the SR.
Cytosolic Calcium Overload
In heart failure, an increase in cytosolic calcium can be caused
by excessive calcium entry into the cytosol or reduced calcium
efflux from the cytosol. Excessive cytosolic calcium entry is184 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.caused by defects in LTCC, NCX, and
store-operated calcium entry (SOCE). In
human cardiomyocytes, cytosolic cal-
cium influx occurs almost entirely through
the LTCC, and during heart failure, thereis increased phosphorylation of the LTCC (Schro¨der et al.,
1998). This has been shown to result in a compensatory leak of
SR calcium through RyR2 (Goonasekera et al., 2012). Modifica-
tion of channel activity through pharmacological inhibition
reduced cardiac remodeling after pressure overload and pre-
vented cardiomyopathy in murine models (Liao et al., 2005;
Semsarian et al., 2002) but was detrimental to survival of patients
with heart failure (Mahe´ et al., 2003). SOCE is a mechanism by
which calcium-release-activated calcium channels (Orai-1) in
the sarcolemma sense depletion of intracellular calcium and
open to allow an influx of extracellular calcium, and this process
may be enhanced during pathological remodeling of heart failure
(Luo et al., 2012). STIM1 is a SR calcium sensor and has a role in
the detection of calcium depletion and the activation of Orai-1
channels. Overexpression of STIM1 in adult rat cardiomyocytes
increased SOCE current and activated pathological hypertro-
phic responses while depletion of STIM1 prevented cardiac hy-
pertrophy and NFAT activation in rats (Hulot et al., 2011).
Reduced calcium efflux across the sarcolemma from the cytosol
is primarily caused by defective activity of NCX. Sodium over-
load in the cytosol inhibits calcium efflux from the cell by the
NCX as it can cause the exchanger to work in reverse mode.
However, more typically during heart failure, NCX is less effective
at extruding intracellular calcium due to a diminished transmem-
brane sodium gradient (Sipido et al., 2002). Some studies have
also found that NCX is upregulated during heart failure (Hasen-
fuss et al., 1999), which could be an initial adaptive response
to compensate for SERCA2a downregulation. However, sus-
tained activation of NCX would be maladaptive, as it would
contribute to a decrease in the SR calcium content due to
increased cytosolic calcium removal.
Figure 2. Structural Interactions between
the SR and Mitochondria and Energy
Metabolism in Cardiac Myocytes
The interfibrillar mitochondria and jSR are in
close proximity, tethered by multiple complexes
includingMFN2.RyR2andSERCA2a interactomes
in the SR are responsible for calcium release and
reuptake from the cytosol during muscle contrac-
tion and relaxation. These interactomes affect
calcium concentration in the cytosol that is avail-
able for uptake by VDAC and MCU in the mito-
chondria. Changes in mitochondrial calcium
concentration influencemultiple processes related
to energy metabolism (ATP synthesis, substrate
usage). Mitochondria also produce ROS as a by-
product of energy metabolism, which affects ATP
production. The energy state of the cell is defined
by ATP and PCr production and consumption.
Multiple proteins involved in cardiac function use
ATP, and their function is affected by the energetic
state of the cell. jSR, junctional sarcoplasmic re-
ticulum; tSR, transverse sarcoplasmic reticulum;
Na,K-ATPase, sodium-potassium ATPase; PMCA,
plasma membrane calcium ATPase; NCX, sodium
calcium exchanger; RyR2, ryanodine receptor
isoform 2; FKBP12.6, RyR2 accessory-binding
protein; TRI, triadin; JNC, junctin; CASQ2, calse-
questrin isoform 2; HRC, histidine-rich calcium-
binding protein; SERCA2a, sarco(endo)plasmic
reticulum calcium ATPase; PLN, phospholamban;
S100A1, S100 calcium-binding protein A1; TN-C,
troponin-C; MFN2, mitofusin isoform 2; MCU,
mitochondrial calcium uniporter; VDAC, voltage-
dependent anion channel; mNCX, mitochondrial
sodium-calcium exchanger; CK, creatine kinase;
PCr, phosphocreatine; Cr, creatine; ROS, reactive
oxygen species.
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During heart failure, one of the most pronounced cellular
changes is an increase in end-diastolic cytosolic calcium levels
and prolongation of the calcium transient during diastole. This
is primarily due to a decrease in SR calcium uptake because of
SERCA2a dysfunction. In both animal models of and patients
with heart failure, there is a reduction in SERCA2a expression
(mRNA and protein levels) and activity (Hasenfuss et al., 1994;
Kiss et al., 1995). PLN reversibly inhibits SERCA2a in cardiac
tissue thereby reducing influx of calcium into the SR. PLN is
phosphorylated at Ser16 by PKA or Thr17 by calcium/calmod-
ulin-dependent protein kinase II (CaMKII) or protein kinase B
(Akt). When phosphorylated at either or both of these sites, the
inhibition of SERCA2a is alleviated and calcium flux into the SR
increases. During heart failure, there are no changes in PLN pro-
tein expression (Movsesian et al., 1994), but some studies have
reported a decrease in PLN mRNA levels in patients with dilated
or ischemic cardiomyopathy (Flesch et al., 1996). The reduction
in SERCA2a expression in heart failure results in an increase in
the PLN-to-SERCA2a ratio, leading to increased inhibition of
SERCA2a. Simultaneously, a reduction in phosphorylation of
PLN has been shown in animal models of heart failure (Huang
et al., 1999) and human failing myocardium (Schwinger et al.,
1999). This is in part due to increased activity of protein phospha-
tase 1 (PP1), which dephosphorylates PLN (Yamada et al., 2006).
Defects in PP1 and its modulation by its inhibitor, inhibitor-1,
have been found in heart failure and have been targeted by ther-
apeutic modalities, which will be discussed in detail later in this
Review.Several mutations in PLN have been identified in patients and
linked to hereditary dilated cardiomyopathy (DCM) (Table 1). The
precise cardiac pathology of the different PLN mutations varies,
but all patients present with cardiac hypertrophy and decreased
ejection fraction. The Arg9Cys mutation was identified in an
American family and results in DCMwith congestive heart failure
(Schmitt et al., 2003). The Arg14 del mutation was first identified
in a Greek patient but has since been found to have a high prev-
alence in the Netherlands (15% of DCM cases) (van der Zwaag
et al., 2013). This mutation causes ‘‘arrhythmogenic cardiomy-
opathy,’’ but the mechanism isn’t understood. The Leu39stop
mutation is a PLN truncation, and no detectable PLN activity
can be found in homozygous patients (Haghighi et al., 2003). Pa-
tients heterozygous for Leu39stop exhibit mild hypertrophy
without diminished cardiac performance and patients homozy-
gous for Leu39stop develop DCM and heart failure. The Arg9Leu
and Arg9His mutations were recently identified in several pa-
tients in Brazil with cardiac hypertrophy and DCM (Medeiros
et al., 2011), and initial molecular characterization has revealed
defects in SERCA2a inhibition by PLN and/or phosphorylation
of PLN by PKA (Ceholski et al., 2012a, 2012b).
Reduced SR Calcium Content
Calcium-buffering proteins within the lumen of the SR serve an
important role during EC coupling. The major calcium-buffering
protein in cardiac SR is calsequestrin isoform 2 (CASQ2), which
has a high capacity and amoderate affinity for calcium and binds
to approximately 50%–75% of total SR calcium (Gyo¨rke et al.,
2009). As a result, CASQ2 reduces the free lumenal calcium con-
centration in order to facilitate SERCA2a-mediated calciumCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 185
Table 1. Disease-Causing Mutations in SR Calcium-Handling Proteins
Protein Mutation Disease Phenotype References
CASQ2 R33Q, Y55C, L167H, E177Q, F189L, K206N, D307H,
P308L
CPVT de la Fuente et al., 2008;
Kirchhefer et al., 2010
HRC S96A Ventricular arrhythmias, DCM Arvanitis et al., 2008
PLN R9C, R9L, R9H DCM Schmitt et al., 2003;
Medeiros et al., 2011;
Haghighi et al., 2006
R14 del Arrhythmogenic cardiomyopathy Haghighi et al., 2003
L39stop Hypertrophy, DCM
RyR2 R414L, I419F, S2246L, V2306I, R2311D, P2328S,
A2387P, A2403T, R2474S, L2534V, L3778F, G3946S,
N4097S, N4104K, E4146K, T4158P, Q4201R, R4497C,
F4499C, N4504I, A4510T, A4608P, V4653F, G4671R,
V4771I, I4848V, A4860G, I4867M, V4880A, N4895D,
P4902L, E4950K
CPVT Yano et al., 2005
R176Q, R420W, L433P, N2386I,
Y2392C, T2504M
ARVD/C2
ARVD/C2, arrhythmogenic right ventricular cardiomyopathy type 2; CPVT, catecholaminergic polymorphic ventricular tachycardia; DCM, dilated car-
diomyopathy. For complete list of RyR2 and CASQ2 mutations, see http://triad.fsm.it/cardmoc/.
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calcium reserve within the SR during systole (Gyo¨rke and Teren-
tyev, 2008). CASQ2 interacts with RyR2 through triadin, which
allows the modulation of RyR2 activity by CASQ2. Although
the mRNA and protein levels of CASQ2 remain unaltered in heart
failure, CASQ2 has been associated with cardiac arrhythmias,
such as catecholaminergic polymorphic ventricular tachycardia
(CPVT) (Kontula et al., 2005) (Table 1). The CPVT phenotype
was confirmed in a transgenic mouse model, where knocking
out the CASQ2 gene caused an autosomal-recessive form of
CPVT with unaltered calcium transients (Knollmann et al., 2006).
Another SR calcium-binding protein thought to have a role in
calcium uptake and release is the histidine-rich calcium-binding
protein (HRC). Found in the lumen of the cardiac SR, HRC has
been shown to interact with SERCA2a and RyR2 through junctin
(an accessory membrane protein), indicating its potentially
important role in the crosstalk between SR calcium storage
and release (Arvanitis et al., 2007) (Figure 2). Overexpression of
HRC in adult rat cardiomyocytes and transgenic mice increased
the calcium storage capacity of the SR but decreased SR cal-
cium release, resulting in depressed contractility (Fan et al.,
2004; Gregory et al., 2006). The protein levels of HRC have
been shown to be significantly reduced in human and animal
models of heart failure (Fan et al., 2004), which may be a
compensatory mechanism that increases calcium release from
the SR in an attempt to improve cardiac contraction. More
recently, a HRCmutation (Ser96Ala) was found to cause defects
in regulation, as evidenced by depressed calcium transients and
prolonged calcium decay, which lead to DCM and ventricular
arrhythmias (Arvanitis et al., 2008; Han et al., 2011) (Table 1).
S100A1 is a calcium-binding protein that has recently
emerged as a key regulator of calcium homeostasis in cardiac
muscle. Preferentially expressed in the left ventricle of the heart,
S100A1 is a membrane protein that localizes to the SR, sarco-
mere, and mitochondria (Figure 2). S100A1 has been shown to
interact with both RyR2 and SERCA2a in the cardiac SR mem-
brane, thereby facilitating calcium release during systole and186 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.calcium reuptake during muscle relaxation, respectively (Kiewitz
et al., 2000; Vo¨lkers et al., 2007). Therefore, S100A1 directly aug-
ments SR calcium uptake and increases SR calcium load. In
addition to being expressed in the SR, S100A1 is also present
in themitochondria where it interacts with F1F0 ATP synthase, re-
sulting in an increase in its activity and increased ATP production
(Boerries et al., 2007). Decreased expression of S100A1 was
shown in animal models of heart failure and human heart sam-
ples with dilated and ischemic cardiomyopathy, suggesting
that S100A1 plays a crucial role in proper cardiac function
(Brinks et al., 2011; Remppis et al., 1996). Indeed, S100A1
knockout mice were shown to develop accelerated congestive
heart failure after myocardial infarction and increased mortality
(Brinks et al., 2011; Remppis et al., 1996). In contrast, transgenic
mice overexpressing S100A1 exhibited improved calcium
handling, enhanced contractile response to b-adrenergic stimu-
lation, and increased survival (Brinks et al., 2011).
SR Calcium Leak
RyR2-mediated release of calcium from the SR into the cytosol is
a key event during EC coupling and is required for cardiac
contraction. During muscle relaxation, it is imperative for RyR2
channels to remain tightly closed in order for SR calcium stores
to be refilled and primed for subsequent muscle contraction.
Aberrant gating of the RyR2 channels has been associated
with cardiac arrhythmias and congestive heart failure (Kushnir
and Marks, 2010; Wehrens and Marks, 2003). It is important to
note that unlike SERCA2a, the expression of RyR2 is unaltered
in heart failure (Sainte Beuve et al., 1997). However, several other
factors can contribute to defective function of RyR2. It has been
reported that increased b-adrenergic signaling results in hyper-
phosphorylation of RyR2 at Ser2808 by PKA, leading to impaired
binding of the channel-stabilizing protein FKBP12.6 (also
referred to as calstabin2) and diastolic leakage of calcium from
the SR during heart failure (Hain et al., 1995; Marx et al., 2000).
Moreover, the levels of protein phosphatase 1 and 2A, both of
which associate with RyR2, were shown to be reduced in pa-
tients with heart failure, suggesting a slower dephosphorylation
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complex, as well as increased calcium sensitivity of RyR2
(Marx et al., 2000). Nevertheless, the mechanism of PKA-medi-
ated hyperphosphorylation of RyR2 during heart failure is under
debate, as several studies reported RyR2 channel activity to be
slightly decreased in response to phosphorylation (Valdivia et al.,
1995; Xiao et al., 2005). CaMKII-dependent phosphorylation of
RyR2 has also emerged as an important modulator of calcium
channel activity in heart failure (Chelu et al., 2009). Studies
have shown elevated CaMKII levels as well as increased
CaMKII-dependent phosphorylation of RyR2 at Ser2008 and
Ser2814 in heart failure (Dobrev and Wehrens, 2014), which
appear to be an alternative mechanism for increased calcium
release from the SR during diastole. Finally, several missense
mutations in RyR2 have been identified in patients with cardiac
arrhythmias (Table 1), specifically CPVT, resulting in reduced
binding affinity for FKBP12.6 and increased permeability of
RyR2 to SR calcium (Priori et al., 2001). Although further work
is required to elucidate the mechanism of RyR2 regulation in
heart failure, stabilization of the RyR2-FKBP12.6 complex ap-
pears to be a promising target for the treatment of heart failure.
An Energy Crisis in the Failing Heart
The high energy demands of the heart must be maintained in
order for it to sustain continuous work. During heart failure, the
dynamic metabolic network in the cardiomyocyte is perturbed,
and these alterations cause energy depletion, directly affecting
contractile function. Mitochondrial dysfunction has been linked
to cardiac arrhythmias and sudden death (Brown et al., 2010).
Heart failure is associated with multiple mitochondrial de-
fects—reduced ATP production, a decline in mitochondrial res-
piratory activity, and structural defects—but it is unknown as
to whether this is due to a reduction in mitochondrial mass or de-
fects in mitochondrial function (Ide et al., 2001; Rosca et al.,
2008; Shen et al., 1999). These multiple mitochondrial perturba-
tions are linked to alterations in calcium signaling and EC
coupling. In the following subsections, we describe the multifac-
eted roles of the mitochondria in the heart, the energetic pheno-
type of the failing heart, and the importance of SR-mitochondria
crosstalk in the cardiomyocyte as well as how it is affected in
heart failure.
Mitochondria in the Human Heart
Mitochondria play a key role in cardiac metabolism and ener-
getics, as they occupy as much as 40% of cell volume (Palmer
et al., 1977). Mitochondria have multifaceted roles in the cardiac
cell, including energy homeostasis, signaling, metabolism, and
mediation of cell death pathways. Consequently, the number,
morphology, and function of mitochondria are regulated accord-
ing to cell-specific requirements. This regulation is largely
controlled by a network of transcription factors, which mediate
replication and transcription of the mitochondrial genome, and
respond to changes in energy metabolism, nutrient availability,
and physiological state of the cell, allowing for adjustments in
mitochondrial biogenesis and function (Hock and Kralli, 2009).
Mitochondria are dynamic organelles that continuously undergo
fission and fusion, and these processes are indispensable to
their proper function within the cell (Chan, 2012). Genetic defects
in transcription factors or genes involved in mitochondrial
biogenesis and dynamics have been linked to multiple pathol-ogies including cancer, heart disease, and neurological disor-
ders (Archer, 2013). While energy metabolism is the primary
role of mitochondria (discussed in detail in the next subsection),
they also have roles in mediating cell signaling and cell death
pathways. The primary mediators of cell signaling in mitochon-
dria are calcium and reactive oxygen species (ROS). In cardiac
myocytes, there are two subpopulations of mitochondria that
differ primarily by their localization—the interfibrillar mitochon-
dria are located adjacent to the junctional SR parallel to the
myofibrils and the subsarcolemmal mitochondria are situated
underneath the plasma membrane—but also have slightly
different biochemical properties and protein and lipid composi-
tion (Palmer et al., 1977). Since they are adjacent to the SR,
interfibrillar mitochondria are exposed to intracellular calcium
transients and are capable of accumulating large amounts of
intracellular calcium in response to calcium flux (Carafoli and
Lehninger, 1964). The mitochondrial calcium uniporter (MCU) is
the primary means for mitochondrial calcium uptake, and its ac-
tivity is dependent on intracellular calcium concentration (Riz-
zuto et al., 2000) (Figure 2). Calcium extrusion from the matrix
is accomplished by the mitochondrial NCX (mNCX), reversal of
the MCU, or a permeability transition of the inner mitochondrial
membrane (Bernardi and Petronilli, 1996; Montero et al., 2001;
Saotome et al., 2005). The accumulation of calcium in mitochon-
dria has been implicated in rate of energy production and activa-
tion of cellular apoptosis and necrosis pathways (Nakayama
et al., 2007). As a byproduct of ATP production, mitochondria
produce ROS that relay stress signals in the cell but can also
jeopardize mitochondrial viability and cause cell damage or
death (Brand et al., 2004). In the cardiomyocyte, this process
has been implicated in ischemia-reperfusion injury (Brand
et al., 2004; Yoshida et al., 2000). Cytosolic calcium overload
and oxidative stress can lead to changes in the permeability of
the mitochondrial inner membrane, which is associated with
opening of the permeability transition pore, leading to dissipation
of the mitochondrial membrane potential, uncoupling of oxida-
tive phosphorylation, loss of ATP, and activation of necrotic
pathways (Walters et al., 2012). In particular, mice that overex-
press cyclophilin D, a regulatory component of the permeability
transition pore, show mitochondrial swelling and spontaneous
cell death while cyclophilin D knockout mice are protected
from ischemia-reperfusion-induced cell death (Baines et al.,
2005). In addition, mitochondrial autophagy (mitophagy) plays
an early cardioprotective role during ischemia-reperfusion in
order to prevent activation of pro-death pathways in favor of
adaptation to stress (Kubli and Gustafsson, 2012).
Energetic Phenotype of the Failing Myocardium
While energetic profiles can differ between various cardiac
pathologies, it has been well established that the failing heart is
energy starved. ATP levels are significantly depleted (25%–
30%) during heart failure, as seen in human heart biopsies and
animal models (Starling et al., 1998). In the canine rapid pacing
heart failure model, a reduction in ATP is observed quickly,
soon after the onset of rapid pacing, but occurs at a slow and
progressive rate (0.35% per day) (Shen et al., 1999). This
reduction occurs before any left ventricular systolic dysfunction
but occurs so gradually that it would be beyond detection until
overt heart failure has already occurred. Whether this depletion
of ATP is a cause or effect of heart disease is unknown, as aCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 187
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examined.
While ATP is the major source of energy in the heart, total cre-
atine and PCr levels are better markers of the energetic state of
the heart, as they are the primary source of cardiac energy
reserve. In the normal heart, approximately two-thirds of the total
creatine pool is phosphorylated via creatine kinase (PCr + ADP +
H+/ creatine + ATP), so the energy is kinetically trapped and
primed as a source of ATP (Figure 2). In animal models and pa-
tients with severe heart failure, total creatine levels fall by as
much as 60% (Katz, 1998). This reduction results in a concomi-
tant decrease in PCr, the depletion of which is more severe than
that of ATP, which results in a decrease in [PCr]/[ATP]. The [PCr]-
to-[ATP] ratio is a better predictor of overall and cardiovascular
mortality than New York Heart Association Class and LV ejection
fraction (Ingwall and Weiss, 2004).
Substrate utilization for energy production is markedly
different in heart failure, described as a ‘‘metabolic shift’’ from
fatty acid oxidation to glucose use through glycolysis (Siddiqi
et al., 2013). This change has been described as a shift to the
fetal phenotype, although aerobic metabolism is still dominant.
Glucose utilization is inefficient at generating energy compared
to fatty acid metabolism but uses less oxygen to generate the
same amount of ATP (Camici et al., 1989). Due to limiting oxygen
in myocardial ischemia, this may be an adaptive response of the
heart. Insulin resistance is also commonly found in patients with
heart failure, as either an etiological mechanism with diabetic
cardiomyopathy or a consequence of heart failure itself (Ashra-
fian et al., 2007), and it impairs insulin-mediated glucose uptake
and leads to the toxic accumulation of triglycerides (Poornima
et al., 2006). In fact, cardiac-specific overexpression of GLUT1
was found to delay the development of heart failure in mice
due to pressure overload by increasing the capacity for glucose
uptake and utilization (Liao et al., 2002).
SR-Mitochondria Crosstalk and Its Implications for
Calcium Dysregulation
The importance of SR-mitochondria crosstalk is demonstrated
by their close physical association and reciprocal functional in-
fluence. Electron tomography experiments have shown the dis-
tance between the SR and mitochondria to be between 10 and
50 nm (Csorda´s et al., 2006), and evidence of a physical associ-
ation was confirmed by electron microscopy (Ramesh et al.,
1998). This is accomplished by the formation of two types of
tethering complexes between the mitochondria and SR: one
group is purely structural, providing only a supportive link be-
tween the two organelles (e.g., Mitofusin-2), and the other is
both structural and functional, also providing signaling commu-
nication between the mitochondria and the SR (e.g., Mitostatin,
RyR2, VDAC) (Eisner et al., 2013; Griffiths and Rutter, 2009)
(Figure 2). Disruption of SR-mitochondria interactions results in
reduced ATP production and triggers stress and apoptotic path-
ways. In fact, ablation of Mitofusin-2 in mouse cardiac myocytes
resulted in accumulation of functionally and morphologically
abnormal mitochondria and ultimately led to DCM (Chen and
Dorn, 2013). It has been known for some time that intracellular
calcium levels influence calcium uptake by mitochondria, but
the high levels of calcium required to induce these changes
were higher than typical maximal physiological relevant calcium
levels (Javadov et al., 2003). It was later discovered that mito-188 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.chondria respond specifically at those sites directly adjacent to
the SR where there are large increases in calcium concentration
in transient microdomains (Garcı´a-Pe´rez et al., 2008). SR cal-
cium release has been shown to be highly regulated by cleft
calcium concentration (the region between the junctional SR
and the T-tubule), and recent developments have allowed the
accurate measurement of calcium microdomains in the cardio-
myocyte. Despa and colleagues developed calcium sensors to
specifically target subcellular microdomains, and their results
demonstrate the existence of a permanent calcium gradient be-
tween the cleft and bulk cytosol during diastole (Despa et al.,
2014). By exploiting these standing gradients, mitochondria act
as calcium sensors, allowing the propagation of the calcium
signal initiated by SR release. Indeed, efficient production of
ATP and its delivery to the SR are influenced by cytosolic and
mitochondrial calcium levels, as several mitochondrial enzymes
are activated by increases in calcium (Denton et al., 1972, 1978;
McCormack and Denton, 1979), and defective energy transfer
between the SR and mitochondria has been implicated in EC
coupling deterioration (Wilding et al., 2006). It has also been pro-
posed that mitochondrial calcium levels can alter the activity of
the F1F0 ATP synthase; although shown to bind calcium directly,
the F1F0 ATP synthase is likely to be regulated via post-transla-
tional modifications and phosphorylation of its g-subunit, which
is sensitive to mitochondrial calcium concentration (Hopper
et al., 2006). It has also been shown that S100A1 can bind to
the F1F0 ATP synthase in a calcium-dependent manner, allowing
for an increase in ATP production (Boerries et al., 2007) (Figure 2).
In addition, ROSmicrodomains may impact SR function and cal-
cium microdomains, as oxidation of cysteine thiol groups of the
RyR receptor has been shown to result in an increase in channel
activity (Zima and Blatter, 2006). In rat cardiac myocytes, mito-
chondrial ROS production resulted in the production of calcium
sparks from the SR (Yan et al., 2008). The integrity of the mutual
relationship between the SR and mitochondria is therefore
imperative for individual organelle and whole cardiomyocyte
function.
Potential Therapies for Heart Failure
Our understanding of normal and pathophysiological calcium
transport and signaling has allowed for the development of ther-
apies that target calcium-handling proteins. During heart failure,
there is cytosolic calcium overload due to SR malfunction.
Recent therapies have been designed to improve SR function,
either by increasing SR calcium uptake or preventing SR calcium
leak. These therapies will be discussed in the context of cardiac
energetics when applicable.
Increasing SR Calcium Uptake
SERCA2a. During heart failure, the expression and activity of
SERCA2a is reduced, and gene transfer of SERCA2a into failing
human cardiomyocytes improved contractility (del Monte et al.,
1999). Similarly, SERCA2a gene transfer improved survival and
cardiac contractility in multiple animal models of heart failure,
including pressure-overload rat (Mu¨ller et al., 2003) and porcine
(Kawase et al., 2008)models. Adenoviral-mediated gene expres-
sion of SERCA2a was also shown to significantly improve car-
diac energetics via an increase in the [PCr]/[ATP] ratio in a rat
model of heart failure (Figure 3A) (del Monte et al., 2001). This
was unexpected given the increased requirements for ATP and
Figure 3. Gene Transfer of SERCA2a
Improves Cardiac Metabolism and
Energetic Function in Failing Hearts
(A) The [PCr]-to-[ATP] ratio and the levels of both
PCr and ATP are lower in failing hearts compared
to healthy hearts. The overexpression of SERCA2a
in failing heart restores the [PCr]-to-[ATP] ratio
toward normal (del Monte et al., 2001).
(B) Linear relationship between the oxygen cost of
calcium handling (VO2) and left ventricular
contractility (eEmax) in normal (-), failing (:) and
failing + SERCA2a (C) hearts. The slope of these
linear relations represents the oxygen cost of left
ventricular contractility. Treatment of failing hearts
by SERCA2a gene therapy improves the energy
cost of left ventricular contractility (Sakata et al.,
2007).
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pression in a sham rat heart resulted in reduced [PCr]/[ATP] ratio.
A later study by the same group showed that short- and long-
term adeno-associated viral (AAV) SERCA2a overexpression in
the same rat model of heart failure restored (decreased) the
oxygen consumption of cardiomyocytes to normal levels
(Figure 3B) (Sakata et al., 2007). The oxygen cost of contractility
is thought to be proportional to the energetic cost of contractility,
both of which are decreased during heart failure. Of note, a more
recent study found that SERCA2a overexpression is limited by
the energy supply of the failing heart in a pressure-overload
transgenic mouse model (Pinz et al., 2011). In this study,
SERCA2a was overexpressed prior to the development of car-
diac hypertrophy induced by pressure overload, and despite
prevention of downregulation of SERCA2a during the progres-
sion of heart failure, there were no overt beneficial effects on car-
diac reserve. Therefore, increasing SERCA2a levels may be
most effective in improving cardiac energetics when heart failure
is established.
Following amultitude of studies in large animal models of heart
failure using AAV carrying SERCA2a through intra-coronary de-
livery, first-in-man clinical gene therapy trials in patients with
advanced heart failure began (Kawase et al., 2008). AAV vectors
offer distinct advantages in that they are safe, transduce the
myocardium efficiently, afford long-term expression, and do
not elicit an immune response. CUPID (Calcium Upregulation
by Percutaneous Administration of Gene Therapy in Cardiac Dis-
ease) is the first clinical trial of AAV1 delivery of SERCA2a
(AAV1.SERCA2a) in patients with advanced heart failure. In
2007, phase I of this study began, with the primary objective be-
ing to investigate the safety and biological effects of restoring
SERCA2a activity in patients with advanced heart failure (Jaski
et al., 2009). AAV1.SERCA2a was administered to 12 patients
by single coronary artery infusion in a dose-escalation manner
(1.4 3 1011–1.0 3 1013 DNase-resistant particles [DRP]). This
trial revealed no safety concerns, and several patients showed
improvements in heart failure parameters and cardiac function.
Phase II of the CUPID trial was a double-blind, placebo-
controlled, randomized study of 39 patients with advanced heart
failure where patients received either placebo or low (6 3 1011
DRP), medium (3 3 1012 DRP), or high (1 3 1013 DRP) doses
of AAV1.SERCA2a (Jessup et al., 2011). After 6 months, patientswho received the high dose displayed an improvement or stabi-
lization of heart failure symptoms and, after 12 months, had
fewer cardiovascular events and shorter hospitalizations.
Three-year follow-up of these patients showed sustained
improvement in clinical event rates in patients receiving high-
dose AAV1.SERCA2a along with persistence of the vector within
the myocardium for up to 31 months (Zsebo et al., 2014). An
international Phase IIb/III trial is currently underway to assess
the effectiveness of AAV1.SERCA2a in improving clinical out-
comes in patients with advanced heart failure (saline versus
AAV1.SERCA2a 1 3 1013 DRP). Other ongoing trials are evalu-
ating the ability of AAV1.SERCA2a delivery to halt adverse left
ventricular remodeling and improve ventricular function in pa-
tients with left ventricular assist devices.
Phospholamban. In failing human myocardium, SERCA2a
expression and activity are decreased but are not accompanied
by a concurrent decrease in PLN expression (Hasenfuss et al.,
1994), resulting in SERCA2a superinhibition and prolonged mus-
cle relaxation due to higher PLN-to-SERCA ratios. Multiple anti-
sense RNA or small hairpin RNA (shRNA) studies to specifically
target and downregulate PLN have been performed in vitro
and in vivo in order to rescue cardiac function (del Monte et al.,
2002; Suckau et al., 2009). A recent large animal study involving
a shRNA against PLN proved to be toxic due to adverse interfer-
ence with microRNA pathways (Bish et al., 2011). However, use
of AAV9-mediated expression of a shRNA to silence PLN re-
sulted in an increase in SERCA2a activity and improved cardiac
function in aortic-banded rats (Suckau et al., 2009). Overexpres-
sion of dominant-negative and pseudo-phosphorylated (Ser16-
to-Glu) forms of PLN have improved cardiac function in animal
models of heart failure (Kaye et al., 2007; Ziolo et al., 2005). How-
ever, the Ser16-to-Glu PLN mutant cannot be phosphorylated
in vivo, which may limit its therapeutic potential.
Protein Phosphatase 1. PLN is phosphorylated by multiple ki-
nases, including PKA, CaMKII, and Akt, but is only known to be
dephosphorylated by protein phosphatase 1 (PP1). When phos-
phorylated, PLN is non-inhibitory and results in an increase in
SR calcium uptake and subsequent increase in force of contrac-
tion. One therapeutic approach to increase the proportion of
phosphorylated PLN is to inhibit the activity of PP1. It is well-es-
tablished that there is increased expression of PP1 during heart
failure (Wittko¨pper et al., 2011). In addition, there is decreasedCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 189
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tor-1 (I-1), a PP1-specific inhibitor, which culminates in
decreased phosphorylation of PLN and increased inhibition of
SERCA2a activity (Wittko¨pper et al., 2011). I-1 is phosphorylated
by PKA, upon which it inhibits PP1, and propagates the
b-adrenergic response in the heart. Since it has an extensive
number of physiological substrates, chronic inhibition of PP1
is not ideal and has been shown to result in hyperphosphoryla-
tion of RyR2, leading to cardiac arrhythmogenesis (Wittko¨pper
et al., 2011). Recent studies have examined the inhibition of
PP1 through its interaction with I-1 as a potential therapeutic
approach to enhance cardiac function in heart failure. A trun-
cated form of I-1 (I-1c) that is constitutively active has been
shown to increase phosphorylation of PLN at Ser16 but have
no effect on phosphorylation of RyR2, troponin I, or myosin-
binding protein C in animal models of heart failure (Nicolaou
et al., 2009). This suggests this construct causes an increase
in calcium uptake into the SR without modification of normal
SR calcium release (Kawashima et al., 2009). In addition, I-1c
overexpression was reported to improve cardiac performance
post-ischemia and was cardioprotective in a mouse model of
heart failure (Nicolaou et al., 2009), indicating that PP1 may be
a promising therapeutic target.
SUMO1. Recently, the small ubiquitin-related modifier 1
(SUMO1) was shown to play an important role in cardiac
contractility (Kho et al., 2011). Through its modification of
SERCA2a, SUMO1 has been shown to enhance SERCA2a ac-
tivity and stability and is thought to have an important role in
maintaining proper cardiac function. In human and animal
models of heart failure, the expression of SUMO1 and resultant
SUMOylation of SERCA2a are reduced. Cardiac-specific over-
expression of SUMO1 by AAV9-mediated gene delivery in
mouse hearts was found to improve SERCA2a protein stability
and activity. More recent studies in porcine models of ischemic
heart failure have shown that SUMO1 gene transfer improves
cardiac contractility and prevents progression of left ventricular
dilatation (Tilemann et al., 2013). In addition, combined delivery
of SUMO1 and SERCA2a genes had synergistic effects on
improvement of cardiac function. The positive effects of
SUMO1 gene delivery were proportional to dosage, with greater
benefits seen with higher doses of SUMO1. Moreover, SUMO1
overexpression in porcine heart failure models has been shown
to protect SERCA2a from oxidative stress during cardiac hyper-
trophy and heart failure (Lee et al., 2014). Although further
studies are needed to better define the role of SUMO1 in heart
failure, current data support the critical role of SERCA2a
SUMOylation and its potential as a therapeutic target in heart
failure.
Preventing SR Calcium Leak
Ryanodine Receptor 2. Hyperphosphorylated or unstable RyR2
channels result in SR calcium leak, leading to decreased SR cal-
cium content and reduced systolic calcium transients, which in
turn cause decreased contractility and reduced cardiac output
(Belevych et al., 2011; Wehrens et al., 2006). One therapeutic
strategy that has been explored to overcome hyperphosphoryla-
tion of RyR2 by PKA or CaMKII is to overexpress FKBP12.6, a
RyR2 regulatory protein. Cardiac-specific overexpression in
mice (Huang et al., 2006) or adenovirus-mediated delivery in iso-
lated rabbit cardiomyocytes (Loughrey et al., 2004) of FKBP12.6190 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.resulted in stabilization of RyR2, increased SR calcium content,
and improved myocyte shortening. Pharmacological interven-
tion in reducing SR calcium leak has also been investigated,
where SR calcium release is inhibited either by altered RyR2
gating or ion translocation. One such compound is JTV-510
(K201), a benzothiazepine, and it was reported to improve car-
diac function by stabilizing the closed state of RyR2 (Ito et al.,
2000; Kaneko et al., 1997). More recently, a new class of com-
pounds called Rycals (K201 derivatives) was shown to reduce
arrhythmic episodes and act as protective agents against heart
failure progression (Bellinger et al., 2009). These drugs are
thought to reduce SR calcium leak by stabilizing the interaction
between RyR2 and FKBP12.6. However, there are conflicting re-
sults on the role of PKA-mediated phosphorylation of RyR2;
therefore, alternative mechanisms may be important for RyR2
dysfunction in heart failure.
S100A1. Another promising therapeutic target for heart failure
is the S100A1 calcium-sensing protein, which interacts with
RyR2 and SERCA2a in the SR and is also present in the mito-
chondria. During heart failure, S100A1 expression is downregu-
lated (Remppis et al., 1996), but in animal models of heart failure
and failing human cardiomyocytes, overexpression of S100A1
significantly improved contractile function, calcium handling,
and cardiac energetics (Most et al., 2004; Remppis et al.,
1996). Due to its interaction with the F1F0 ATP synthase,
S100A1 treatment has been shown to improve [PCr]-to-[ATP]
and [NADH]-to-[NAD+] ratios in human failing cardiomyocytes
(Brinks et al., 2011).Perspectives
Recent improvements in our understanding of calcium cycling
mechanisms in cardiomyocytes have led to novel therapies for
heart failure. These approaches mostly include targeting SR cal-
cium handling proteins that have altered activity and/or expres-
sion during disease. Current therapies are primarily targeted at
increasing SR calcium uptake or preventing SR calcium leak,
and many are currently being assessed in animal models or pa-
tients with heart failure. Cardiac energetics should also be
considered in therapies targeting SR calcium proteins, as dysre-
gulation of cardiac calcium andmetabolism appear to be symbi-
otic in heart failure. Some current therapies have progressed in
phases of evaluation after having shown early signs of success
(SERCA2a), while others are earlier in development (SUMO1,
S100A1). An emphasis on SR calcium handling proteins and car-
diac energetics will pave the way for future advances in new
treatment options for heart failure.AUTHOR CONTRIBUTIONS
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